Enhertu Shows Clinically Meaningful Activity in HER2 Mutant NSCLC: Daiichi/AZ

Daiichi Sankyo/AstraZeneca’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) delivered clinically meaningful tumor responses in certain patients with HER2 mutant non-small cell lung cancer (NSCLC), the latest PII data show. The global PII DESTINY-Lung02 study investigated Enhertu in previously treated patients...read more